| Dr Charles D Cibula, DPM | |
|
4508 Chadwick Rd, Cedar Valley Podiatry Pc, Cedar Falls, IA 50613-7958 | |
| (319) 277-4508 | |
| (319) 277-8908 |
| Full Name | Dr Charles D Cibula |
|---|---|
| Gender | Male |
| Speciality | Podiatry |
| Experience | 18 Years |
| Location | 4508 Chadwick Rd, Cedar Falls, Iowa |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1750590246 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 213ES0103X | Podiatrist - Foot & Ankle Surgery | BM25495090685 (Michigan) | Secondary |
| 213ES0103X | Podiatrist - Foot & Ankle Surgery | 000836 (Iowa) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Buchanan County Health Center | Independence, IA | Hospital |
| Allen Hospital | Waterloo, IA | Hospital |
| Mercyone Oelwein Medical Center | Oelwein, IA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Cedar Valley Podiatry Pc | 4880586288 | 4 |
News Archive
Cempra Pharmaceuticals today announced the successful completion of Phase 1 clinical trials of its oral formulation of CEM-101, which showed good tolerability in those studies. The company also announced plans to submit an IND to the FDA to begin a Phase 1 study with the company's intravenous formulation of CEM-101 in mid-2010.
A new article by infection control expert William Jarvis, M.D., President, Jason and Jarvis Associates, LLC, highlights the importance of patient safety features in the design of IV needleless connectors.
Also in the news, a new Wall Street Journal poll finds that GOP presidential hopeful Mitt Romney is experiencing a resurgence, just as President Barack Obama's approval rating hit its highest point since last May.
Affymetrix, Inc. today reported that based on preliminary financial data, the Company expects total revenue for the second quarter of 2010 to be in the range of $71-72 million, as compared to the Company's previous guidance in the range of $80-82 million. The company expects product revenue for the second quarter of 2010 to be approximately $65-66 million, including instrument sales of approximately $4-5 million and consumable sales of approximately $60-61 million.
Researchers at the Joslin Diabetes Center have shown that an enzyme found in the mitochondria of cells is decreased in the skeletal muscle of those with diabetes, a finding that could lead to the development of drugs to boost the activity of this enzyme in an effort to fight the disease.
› Verified 6 days ago
| Provider Name | Cedar Valley Podiatry Pc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1932139243 PECOS PAC ID: 4880586288 Enrollment ID: O20040329001546 |
News Archive
Cempra Pharmaceuticals today announced the successful completion of Phase 1 clinical trials of its oral formulation of CEM-101, which showed good tolerability in those studies. The company also announced plans to submit an IND to the FDA to begin a Phase 1 study with the company's intravenous formulation of CEM-101 in mid-2010.
A new article by infection control expert William Jarvis, M.D., President, Jason and Jarvis Associates, LLC, highlights the importance of patient safety features in the design of IV needleless connectors.
Also in the news, a new Wall Street Journal poll finds that GOP presidential hopeful Mitt Romney is experiencing a resurgence, just as President Barack Obama's approval rating hit its highest point since last May.
Affymetrix, Inc. today reported that based on preliminary financial data, the Company expects total revenue for the second quarter of 2010 to be in the range of $71-72 million, as compared to the Company's previous guidance in the range of $80-82 million. The company expects product revenue for the second quarter of 2010 to be approximately $65-66 million, including instrument sales of approximately $4-5 million and consumable sales of approximately $60-61 million.
Researchers at the Joslin Diabetes Center have shown that an enzyme found in the mitochondria of cells is decreased in the skeletal muscle of those with diabetes, a finding that could lead to the development of drugs to boost the activity of this enzyme in an effort to fight the disease.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Charles D Cibula, DPM 4508 Chadwick Rd, Cedar Valley Podiatry Pc, Cedar Falls, IA 50613-7958 Ph: (319) 277-4508 | Dr Charles D Cibula, DPM 4508 Chadwick Rd, Cedar Valley Podiatry Pc, Cedar Falls, IA 50613-7958 Ph: (319) 277-4508 |
News Archive
Cempra Pharmaceuticals today announced the successful completion of Phase 1 clinical trials of its oral formulation of CEM-101, which showed good tolerability in those studies. The company also announced plans to submit an IND to the FDA to begin a Phase 1 study with the company's intravenous formulation of CEM-101 in mid-2010.
A new article by infection control expert William Jarvis, M.D., President, Jason and Jarvis Associates, LLC, highlights the importance of patient safety features in the design of IV needleless connectors.
Also in the news, a new Wall Street Journal poll finds that GOP presidential hopeful Mitt Romney is experiencing a resurgence, just as President Barack Obama's approval rating hit its highest point since last May.
Affymetrix, Inc. today reported that based on preliminary financial data, the Company expects total revenue for the second quarter of 2010 to be in the range of $71-72 million, as compared to the Company's previous guidance in the range of $80-82 million. The company expects product revenue for the second quarter of 2010 to be approximately $65-66 million, including instrument sales of approximately $4-5 million and consumable sales of approximately $60-61 million.
Researchers at the Joslin Diabetes Center have shown that an enzyme found in the mitochondria of cells is decreased in the skeletal muscle of those with diabetes, a finding that could lead to the development of drugs to boost the activity of this enzyme in an effort to fight the disease.
› Verified 6 days ago
Dr. Philip J Morreale, DPM Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 4508 Chadwick Rd, Cedar Falls, IA 50613 Phone: 319-277-4508 Fax: 319-277-8908 | |
Dr. Richard L. Bremner, D.P.M. Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 226 Blue Bell Road, Cedar Falls, IA 50613 Phone: 319-575-5800 Fax: 319-575-5855 | |
Nicholas Richard Schmerbach, DPM Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 4508 Chadwick Rd, Cedar Falls, IA 50613 Phone: 319-277-4508 Fax: 319-277-8908 | |
Dr. Ronald G Cervetti, DPM Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 4508 Chadwick Rd, Cedar Falls, IA 50613 Phone: 319-277-4508 Fax: 319-277-8908 | |
Cedar Valley Podiatry, Pc Podiatrist Medicare: Medicare Enrolled Practice Location: 4508 Chadwick Rd, Cedar Falls, IA 50613 Phone: 319-277-4508 Fax: 319-277-8908 |